NCR-201

N/A

Report date: 2025/12/23 20:00:10

Base Information

Drug NameNCR-201
Drug Alias NameNCR201NCR-201
ClassificationCell and gene therapy > Cell therapy > Somatic cell > Dopaminergic neural orogenitor cell therapyCell and gene therapy > Cell therapy > Source of cells > iPSC-derived
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesZhongsheng Traceability (Guangzhou) Biotechnology Co LtdAnhui Nuwacell Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhongsheng Traceability (Guangzhou) Biotechnology Co LtdAnhui Nuwacell Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A